Neurotensin (8-13) (trifluoroacetate salt)
目录号 : GC44386
A neuropeptide
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Neurotensin (8-13) is a neuropeptide that corresponds to the C-terminal residues 8-13 of neurotensin that binds to rat synaptic membranes with a Ki value of 13 nM. It induces contraction of guinea pig ileum (EC50 = 25 nM) and induces contraction of rat fundus equipotently to full length neurotensin (EC50s = 1.29 and 1.58 nM, respectively). In vivo, neurotensin (8-13) has antinociceptive effects in a mouse tail pressure test (ED50 = 50 nmol per animal). It induces extracellular dopamine release in the prefrontal cortex in rats. Neurotensin (8-13) also decreases diastolic blood pressure in a dose-dependent manner in normotensive rats without affecting heart rate.
| Cas No. | SDF | ||
| Canonical SMILES | [H]N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N1CCC[C@H]1C(N[C@H](C(N[C@]([C@H](CC)C)([H])C(N[C@@H](CC(C)C)C(O)=O)=O)=O)CC2=CC=C(O)C=C2)=O)=O)=O.FC(F)(C(O)=O)F | ||
| 分子式 | C38H64N12O8•XCF3COOH | 分子量 | 817 |
| 溶解度 | Water: 1 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.224 mL | 6.12 mL | 12.2399 mL |
| 5 mM | 0.2448 mL | 1.224 mL | 2.448 mL |
| 10 mM | 0.1224 mL | 0.612 mL | 1.224 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Peptide characterization with a sulfoethyl aspartamide column
J Chromatogr 1988 Jun 29;443:63-71.PMID:2844842DOI:10.1016/s0021-9673(00)94783-6
A strong cation-exchange (SCX) high-performance liquid chromatography column (sulfoethyl aspartamide, 200 x 4.6 mm) was used to analyze more than 50 peptides, ranging in length from 5 to 20 residues. These data show that the elution positions of the peptides increase monotonically with the number of positively charged residues. [A 60-min linear gradient of 0 to 100% eluent B at 1 ml/min was used, where eluent A is 5 mM phosphate (pH 3.0)-acetonitrile (75:25) and eluent B is eluent A + 0.5 M sodium chloride.] A comparison of SCX with a standard C18 reversed-phase (RP) column [60-min linear gradient of 0 to 60% B at 1 ml/min, where eluent A is 0.1% trifluoroacetic acid (TFA), and eluent B is 0.095% TFA-acetonitrile (10:90)] further demonstrates the utility of SCX in peptide characterization. SCX separated an (Arg)3-containing peptide from the Arg-deleted peptide while RP could not. In addition, SCX and RP resolved the methionine oxidation products of ACTH (4-10) (RP: Met [O] less than Met [O2] less than Met; SCX; Met [O] less than Met less than Met [O2]), suggesting a mixed-mode mechanism for the ion-exchange system. Finally, SCX separated the sulfated and non-sulfated forms of cholecystokinin (26-33) and Leu-enkephalin as well as the N-terminal acetylated forms of Neurotensin \(8-13\) and angiotensinogen (1-14) from the respective unmodified peptides.